CD19 and B-cell chronic lymphocytic leukemia: In a pivotal Phase I/II trial of the MD Anderson Cancer Centre, 11 patients with relapsed or refractory CD19‐positive cancer (non‐Hodgkin's lymphoma or chronic lymphocytic leukaemia) were injected with UCB‐derived HLA‐mismatched anti‐CD19 CAR‐NK cells.